Sevelamer carbonate

Annals of Pharmacotherapy

Volumn 44, Issue 1, 2010, Pages 127-134

  Barna, Mary M ^a,b   Kapoian, Toros ^c   O'Mara, Neeta Bahal ^d  

^a RUTGERS UNIVERSITY   (United States)

^b Capital Health Fuld Campus ^*  (United States)

^c ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^d Dialysis Clinics Inc   (United States)

Author keywords

Chronic kidney disease; Hyperphosphatemia; Sevelamer carbonate

Indexed keywords

ALUMINUM HYDROXIDE; BICARBONATE; CALCIUM; CALCIUM ACETATE; CALCIUM CARBONATE; CHLORIDE; CIPROFLOXACIN; DIGOXIN; ENALAPRIL; IRON; LANTHANUM CARBONATE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MAGNESIUM HYDROXIDE; METOPROLOL; PHOSPHATE BINDING AGENT; PHOSPHORUS; RENVELA; SEVELAMER; SEVELAMER CARBONATE; UNCLASSIFIED DRUG; WARFARIN;

ABDOMINAL PAIN; BICARBONATE BLOOD LEVEL; CALCIFICATION; CALCIUM BLOOD LEVEL; CHLORIDE BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED STUDY; DIALYSIS; DIARRHEA; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TOXICITY; DRUG WITHDRAWAL; DYSPEPSIA; FECES IMPACTION; FLATULENCE; GASTROINTESTINAL DISEASE; HUMAN; HYPERPHOSPHATEMIA; ILEUS; INTESTINE OBSTRUCTION; INTESTINE PERFORATION; MEDLINE; METABOLIC ACIDOSIS; NAUSEA; PATIENT COUNSELING; PHARMACODYNAMICS; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; PRURITUS; RASH; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; VOMITING;

CHELATING AGENTS; HUMANS; HYPERPHOSPHATEMIA; KIDNEY FAILURE, CHRONIC; POLYAMINES;

EID: 74549184101     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1M291     Document Type: Review

References (23)

1. National Kidney Foundation. New York: National Kidney Foundation, Inc.; c2007. www.kidney.org (accessed 2007 Jun 12).
2. Coresh J, Astor BC, Greene T, et al. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 2003;41:1-12.
3. US Renal Data System. USRDS 2006 Annual Data Report: atlas of endstage renal disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2006.
4. Collins AJ. Anaemia management prior to dialysis: cardiovascular and cost-benefit observations. Nephrol Dial Transplant 2003;18:ii2-6.
5. National Kidney Foundation: KDOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003;42:S1-S202.
6. Hudson JQ, Johnson CA. Chronic kidney disease. In: Koda-Kimble MA, Young LY, Kradjan WA, et al., eds. Applied therapeutics: the clinical use of drugs. 8th ed. Philadelphia: Wolters Kluwer Health, 2008:32-1-32-36.
7. Kidney Disease: Improving Global Outcomes (KDIGO) CKD -MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD -MBD). Kidney Int 2009;76:S1-130.
8. Chertow GM, Buke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002;62:245-52.
9. Block GA, Spiegel DM, Ehrlich J, et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to dialysis. Kidney Int 2005;68:1815-24.
10. Braun J, Asmus HG, Holzer H, et al. Long term comparison of a xalium free phosphate binder and calcium-phosphorus metabolism and cardiovascular calcification. Clin Nephrol 2004;62:104-15.
11. Block GA, Raggi P, Bellasi A, Kooienga L, Spiegel DM. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int 2007;71:438-41.
12. Suki WN, Zabaneh R, Cangiano JL, et al. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int 2007;72:1130-7.
13. St. Peter WL, Liu J, Weinhandl E, Fan Q. A comparison of sevelamer and calcium-based phosphate binders on mortality, hospitalization, and morbidity in hemodialysis: a secondary analysis of the Dialysis Clinical Outcomes Revisited (DCOR) randomized trial using claims data. Am J Kidney Dis 2008;51:445-54.
14. Red book. Montvale, NJ: Thomson PDR, 2009.
15. Package insert. Renagel (sevelamer hydrochloride). Cambridge, MA: Genzyme Corporation, November 2007.
16. Package insert. Renvela (sevelamer carbonate). Cambridge, MA: Genzyme Corporation, November 2007.
17. Wilkes BM, Reiner D, Kern M, et al. Simultaneous lowering of serum phosphate and LDL-cholesterol by sevelamer hydrochloride (Renagel) in dialysis patients. Clin Nephrol 1998;50:381-6.
18. Plone M, Petersen J, Rosenbaum D, Burke SK. Sevelamer, a phosphatebinding polymer, is a non-absorbed compound. Clin Pharmacokinet 2002;41:517-23.
19. Delmez J, Block G, Robertson J, et al. A randomized, double-blind, crossover design study of sevelamer hydrochloride and sevelamer carbonate in patients on hemodialysis. Clin Nephrol 2007;68:386-91.
20. Ketteler M, Rix M, Fan S, et al. Efficacy and tolerability of sevelamer carbonate in hyperphosphatemia patients who have chronic kidney disease and are not on dialysis. Clin J Am Soc Nephrol 2008;3:1125-30.
21. Fan S, Ross C, Mitra S, et al. A randomized, crossover study of sevelamer carbonate powder and sevelamer hydrochloride tablets in chronic kidney disease patients on haemodialysis. Nephrol Dial Transplant 2009;24:3794-9.
22. Pruchnicki MC, Coyle JD, Hoshaw-Woodward S, Bay WH. Effect of phosphate binders on supplemental iron absorption in healthy subjects. J Clin Pharmacol 2002;42:1171-6.
23. Kays MB, Overholser BR, Mueller BA, et al. Effects of sevelamer hydrochloride and calcium acetate on the oral bioavailability of ciprofloxacin. Am J Kidney Dis 2003;42:1253-9.